(Q37789148)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844563%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Do we have to kill the last CML cell? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844563%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844563%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

T P Hughes

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844563%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

J V Melo

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844563%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

16 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844563%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844563%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844563%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844563%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

193-200

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844563%20AND%20SRC:MED&resulttype=core&format=json

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Discontinuation of imatinib therapy after achieving a molecular response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using str

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' by Steinbach and Debatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Influence of stochastics on quantitative PCR in the detection of minimal residual disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Dynamics of chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

IFNalpha activates dormant haematopoietic stem cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Interferon therapy in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Development and dynamics of robust T-cell responses to CML under imatinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host dis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Dasatinib suppresses in vitro natural killer cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Chronic myeloid leukaemia as a model of disease evolution in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

7 January 2021

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

7 January 2021

Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

7 January 2021

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

7 January 2021

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

7 January 2021

Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

7 January 2021

BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

7 January 2021

Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.197

7 January 2021

Identifiers

DOI

10.1038/LEU.2010.197

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844563%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference